Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis.
Tack
C J
CJ
Department of Internal Medicine, 463, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. c.tack@aig.umcn.nl
Kleijwegt
F S
FS
Van Riel
P L C M
PL
Roep
B O
BO
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000276:immunology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept